The Office of Public Health Genomics (OPHG) provides updated and credible information on how genomic
information and family health history can improve health and influence policy and practice. We highlight
news and information on the use of genomic tests and other applications, including family health history,
in clinical and public health practice and programs, along with relevant data, policy, and legislation. We hope the update is informative to practitioners, policy makers, consumers, and researchers. Please send
your comments to: genetics@cdc.gov.
Reports and Publications
Cancer
- A new genome-driven integrated classification of breast cancer and its implications
Dawson S et al. The EMBO Journal 8 Feb 2013 - A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study
C.A. Drukker, J.M. Bueno-de-Mesquita, V.P. Retèl, et al. International Journal of Cancer 2013- Confirmed: MammaPrint predicts treatment in breast cancer, Medscape, Feb 8 [by free subscription only]
- Dealing with the unexpected: Consumer responses to direct-access BRCA mutation testing
Uta Francke, Cheri Dijamco, Amy K. Kiefer, et al. Peer Journal 2013 Feb 12- Consumers have few negative reactions to the results of genetic testing for cancer mutations, EurekAlert, Feb 12
- Evaluating use characteristics for the Oncotype Dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast Cancer
Chen C et al. J Oncol Practice February 2013 - Increasing Lynch syndrome identification through establishment of a hereditary colorectal cancer registry.
Sturgeon D et al, Dis Colon Rectum. 2013 Mar;56(3):308-14 - miRCancer: a microRNA–cancer association database constructed by text mining on literature
Boya Xie, et al. Bioinformatics Feb 2013
- Melanoma genetic testing, counseling, and adherence to skin cancer prevention and detection behaviors
Glanz KL, et al. Cancer Epidemiol Biomarkers Prev 2013 Feb - Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: A report from the women's environmental cancer and radiation epidemiology study
Reiner AS et al. J Clin Oncol Feb 1 - Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma
National Institute of Health and Clinical Excellence Technology appraisals, TA269, 2012 Dec- NICE guidance on vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma
Perampaladas K, et al. Lancet Oncol 2013 Jan;14(1):20-1
- NICE guidance on vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma
No hay comentarios:
Publicar un comentario